(Q43628295)

25 November 2017

title

Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation (English)

1 reference

25 November 2017

1 reference

9

G Ehninger

1 reference

25 November 2017

10

M Bornhäuser

1 reference

25 November 2017

5

U Platzbecker

1 reference

25 November 2017

A Jenke

1

1 reference

25 November 2017

U Renner

2

1 reference

25 November 2017

M Richte

3

1 reference

25 November 2017

J Freiberg-Richter

4

1 reference

25 November 2017

A Helwig

6

1 reference

25 November 2017

H M Thiede

7

1 reference

25 November 2017

K Schäfer-Eckart

8

1 reference

25 November 2017

publication date

1 June 2001

1 reference

25 November 2017

published in

Clinical Transplantation

1 reference

25 November 2017

volume

15

1 reference

25 November 2017

issue

3

1 reference

25 November 2017

page(s)

176-184

1 reference

The use of mycophenolate mofetil in transplant recipients

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150306.X

Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150306.X

Clinical pharmacokinetics of mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150306.X

Determination of mycophenolic acid and mycophenolate mofetil by high-performance liquid chromatography using postcolumn derivatization

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150306.X

Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150306.X

Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150306.X

European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150306.X

7 January 2021

Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150306.X

7 January 2021

Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150306.X

7 January 2021

Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150306.X

7 January 2021

Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150306.X

7 January 2021

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150306.X

7 January 2021

The monitoring of immunosuppressive drugs: a pharmacodynamic approach

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150306.X

7 January 2021

10.1034/J.1399-0012.2001.150306.X

Identifiers

DOI

1 reference

25 November 2017

1 reference